CA

CAMP

CAMPHealthcareNASDAQ

Biotechnology

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$3.5M
+436.5% YoY
Net Income
-$80.4M
-55.2% YoY
EBITDA
-$50.4M
+1.9% YoY
Free Cash Flow
-$12.8M

Scan Results

Daily timeframe
1 recent day hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Aug 28 MACD Negative CrossoverHistogram -0.0561, negative momentum
Aug 27 MACD Negative CrossoverHistogram -0.0364, negative momentum
About CAMP

Headquartered within the healthcare sector, CAMP focuses on Biotechnology services and products. Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. At a $276.7M market cap, CAMP ranks as a micro-cap company within healthcare. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.

Where CAMP stands vs its 150-day and 200-day moving averages

As of the August 28, 2026 close, CAMP finished 3.94% below its 150-day moving average ($4.31) and 7.59% below its 200-day moving average ($4.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is CAMP overbought or oversold?

At the August 28, 2026 close, CAMP's RSI(14) was 48.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$276.7M
Fwd P/E-5.55
EPS$-2.31
52W Change+121.6%
ROE-545.9%
Analysis

CAMP holds $86.4M in cash against $2.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$12.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -545.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.

The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CAMP and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms